Lexaria Bioscience Corp. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Discontinued Operations (Tables)

Discontinued Operations (Tables)

6 Months Ended

Feb. 28, 2022

Discontinued Operations

Schedule on gain on asset disposal

Gain on asset disposal
Book value of assets sold		$	-
Cash consideration			273,373
Shares received			468,264
Shares receivable			781,067
Promissory note			-
		$	1,522,704

		SIX MONTHS ENDED
		February 28,
		2022				2021
Revenue		$	-			$	3,000
Operating Expenses			-				25,000
Net Income (loss)		$	-			$	(22,000	)

		SIX MONTHS ENDED
		February 28,
		2022				2021
Cash flows used in discontinued operating activities
Net income		$	-			$	(22,000	)
Change in working capital			-				105,000
Net cash used in discontinued operating activities		$	-			$	83,000

Net cash provided by discontinued operations			-			$	83,000